Hirajith GH, Vice President and Head of Research Services, MedGenome Inc.
2022 was an eventful year,
Our journey in 2022 focused on providing the best customer experience for the services and solutions we provided. Expanded portfolio of services and solutions, plus tissue dissociation and nuclear isolation services to support single-cell customers, streamlined antibody discovery using high-throughput single B-cell receptor sequencing, tumors TSO500 Targeted Panel, Single Cell and Bulk Epigenetics Assays for Scientific Research. By incorporating automation at multiple project stages and introducing new sequencing capabilities in 2022, we will be Improved the turnaround time of . Year.
We have also deployed a series of advanced, interactive analytical reports for each assay through our proprietary ManGo platform with new data representations. Scaling up this bioinformatics capability is in line with our aim to help biologists and researchers maximize the utility of their genomic data.
After each project was delivered, we worked with our clients to discuss the data and subsequent analysis to ensure the results met the researchers’ needs.
We have built a streamlined system and communication process for sample and data management with our customers. This allowed us to build transparency and trust.
We will continue to provide high quality support for your projects in 2023. In 2023, we will use lab resources to optimize spatial transcriptomics and Hi-C assays in-house and expand our service portfolio. We provide end-to-end services to our customers by supporting bioinformatics analysis and tools.
MedGenome has experienced R&D talent to engage with you for antibody discovery solutions and protein expression services.
As sample volumes increase, we are committed to investing more in sequencing capacity in 2023 to maintain project turnaround time (TAT). HiSeq X service will be retired by the end of this year.
Also, customers looking to access South Asian genomic datasets for specific disease areas (rare diseases, oncology, neurodegenerative diseases, hematologic diseases, metabolic diseases) for discovery or genetic modification studies. We are also a preferred partner for MedGenome will be able to accelerate these studies with great impact due to its vast network of collaborations with hospitals in India.
The pandemic has tested the quality of our systems, processes and team members without question. This demonstrates the importance of value-added engagement with customers that MedGenome strives for. As we head into 2023, MedGenome looks forward to continuing these relationships and advancing our customers’ genomics research.
#Genomicsservices, #genomicsresearch, #genomeprojects, #customer, #relationship, #TSO500, #ManGo Platform
https://research.medgenome.com/medgenome-is-a-preferred-partner-for-ngs-and-informatics-expertise/ MedGenome is your preferred partner for NGS and informatics expertise